MedTrace Logo

Effect of Gabapentin on Kidney Function Following Laparoscopic Sleeve Gastrectomy(LSG)

NCT06254183 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 90

Last updated 2026-02-25

No results posted yet for this study

Summary

Assessment of the effect of gabapentin as an analgesic replacement on the Kidney function following Laparoscopic sleeve gastrectomy for Morbid Obese Patients by measuring two biomarkers: NGAL (Neutrophil gelatinase-associated lipocalin)and DKK3 (Dickkopf-3)

Conditions

Interventions

PROCEDURE

Laparoscopic Sleeve Gastrectomy

Standard laparoscopic sleeve gastrectomy performed under general anesthesia according to institutional protocol, with gastric resection over a calibration bougie.

DRUG

gabapentin 1200 mg

A single oral dose of 1200 mg gabapentin administered 1 hour prior to induction of anesthesia for laparoscopic sleeve gastrectomy. The medication is given as two 600 mg tablets ((Unipharma Co.)

Sponsors & Collaborators

  • Tanta University

    lead OTHER

Principal Investigators

  • Kholoud Salah Ibraahim Amin, Bsc. · Delta university for Sciences and Technology

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-12-01
Primary Completion
2025-05-01
Completion
2025-11-30

Countries

  • Egypt

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06254183 on ClinicalTrials.gov